Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 1
1999 1
2002 1
2008 1
2010 2
2011 2
2012 1
2013 1
2016 1
2022 1
2023 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Biomarkers for Alzheimer's disease therapeutic trials.
Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B; Oxford Task Force Group. Hampel H, et al. Prog Neurobiol. 2011 Dec;95(4):579-93. doi: 10.1016/j.pneurobio.2010.11.005. Epub 2010 Dec 2. Prog Neurobiol. 2011. PMID: 21130138 Review.
Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial.
Rafii MS, Sol O, Mobley WC, Delpretti S, Skotko BG, Burke AD, Sabbagh MN, Yuan SH, Rissman RA, Pulsifer M, Evans C, Evans AC, Beth G, Fournier N, Gray JA, Dos Santos AM, Hliva V, Vukicevic M, Kosco-Vilbois M, Streffer J, Pfeifer A, Feldman HH. Rafii MS, et al. Among authors: sol o. JAMA Neurol. 2022 Jun 1;79(6):565-574. doi: 10.1001/jamaneurol.2022.0983. JAMA Neurol. 2022. PMID: 35532913 Free PMC article. Clinical Trial.
Toward an Alzheimer's disease diagnosis via high-resolution blood gene expression.
Fehlbaum-Beurdeley P, Jarrige-Le Prado AC, Pallares D, Carrière J, Guihal C, Soucaille C, Rouet F, Drouin D, Sol O, Jordan H, Wu D, Lei L, Einstein R, Schweighoffer F, Bracco L. Fehlbaum-Beurdeley P, et al. Among authors: sol o. Alzheimers Dement. 2010 Jan;6(1):25-38. doi: 10.1016/j.jalz.2009.07.001. Alzheimers Dement. 2010. PMID: 20129318
Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase 1b/2a, multicentre, double-blind, randomised, placebo-controlled study.
Sol O, Mermoud J, Hallikainen M, Kurl S, Rinne J, Dautzenberg P, Vijverberg EGB, Mummery C, Börjesson-Hanson A, Jonsson M, Ritchie C, Pennington C, Vukicevic M, Gollwitzer E, Fiorini E, Hickman DT, Hliva V, Gray J, Gerasymchuk V, Wagg J, Fournier N, Lê B, Kezic I, Steukers L, Triana-Baltzer G, Theunis C, Streffer J, Kosco-Vilbois M, Pfeifer A, Scheltens P. Sol O, et al. EBioMedicine. 2025 Sep 18;120:105940. doi: 10.1016/j.ebiom.2025.105940. Online ahead of print. EBioMedicine. 2025. PMID: 40972226 Free article.
15 results